Brokerages Set KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) PT at $23.80

Shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) have been assigned an average rating of “Buy” from the seven ratings firms that are covering the firm, Marketbeat reports. Six investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average 1-year price target among brokers that have issued ratings on the stock in the last year is $23.80.

A number of equities analysts have recently commented on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of KalVista Pharmaceuticals in a report on Monday, December 9th. Citizens Jmp upgraded KalVista Pharmaceuticals to a “strong-buy” rating in a research note on Friday, January 31st. Bank of America started coverage on KalVista Pharmaceuticals in a report on Wednesday, December 18th. They issued a “buy” rating and a $22.00 target price on the stock. HC Wainwright reaffirmed a “buy” rating and set a $20.00 price target on shares of KalVista Pharmaceuticals in a report on Friday, March 14th. Finally, TD Cowen initiated coverage on shares of KalVista Pharmaceuticals in a research note on Tuesday, January 7th. They issued a “buy” rating and a $30.00 price objective on the stock.

Insiders Place Their Bets

In other news, major shareholder Venrock Healthcare Capital Par bought 43,707 shares of the stock in a transaction on Thursday, January 30th. The shares were bought at an average price of $8.76 per share, with a total value of $382,873.32. Following the completion of the acquisition, the insider now owns 4,986,480 shares of the company’s stock, valued at approximately $43,681,564.80. This trade represents a 0.88 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Paul K. Audhya sold 3,125 shares of the firm’s stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $9.82, for a total value of $30,687.50. Following the completion of the transaction, the insider now owns 100,334 shares of the company’s stock, valued at approximately $985,279.88. This represents a 3.02 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have purchased 236,055 shares of company stock worth $2,162,146 and have sold 17,292 shares worth $184,625. Insiders own 10.50% of the company’s stock.

Institutional Trading of KalVista Pharmaceuticals

Institutional investors and hedge funds have recently modified their holdings of the business. Aquatic Capital Management LLC purchased a new position in shares of KalVista Pharmaceuticals during the 4th quarter worth approximately $44,000. Tower Research Capital LLC TRC boosted its stake in shares of KalVista Pharmaceuticals by 666.9% during the fourth quarter. Tower Research Capital LLC TRC now owns 6,327 shares of the specialty pharmaceutical company’s stock valued at $54,000 after acquiring an additional 5,502 shares during the last quarter. Legal & General Group Plc boosted its stake in shares of KalVista Pharmaceuticals by 22.5% during the 4th quarter. Legal & General Group Plc now owns 8,144 shares of the specialty pharmaceutical company’s stock worth $69,000 after purchasing an additional 1,494 shares during the last quarter. Martin Worley Group acquired a new stake in KalVista Pharmaceuticals during the fourth quarter worth approximately $86,000. Finally, China Universal Asset Management Co. Ltd. raised its holdings in KalVista Pharmaceuticals by 24.7% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 10,329 shares of the specialty pharmaceutical company’s stock valued at $87,000 after acquiring an additional 2,043 shares during the last quarter.

KalVista Pharmaceuticals Trading Up 3.0 %

Shares of NASDAQ KALV opened at $12.25 on Friday. The stock has a market cap of $609.02 million, a P/E ratio of -3.37 and a beta of 0.76. KalVista Pharmaceuticals has a twelve month low of $7.30 and a twelve month high of $15.50. The stock has a 50 day moving average of $10.22 and a two-hundred day moving average of $10.23.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).